AstraZeneca diabetes drug combination meets main goals in Phase III study
AstraZeneca said a combination of two diabetes medications significantly lowered blood sugar, weight and blood pressure in a Phase III trial.
The phase III DURATION-8 trial showed that Bydureon, taken just once a week in combination with Forxiga once daily significantly reduced blood sugar, compared with the individual medicines alone in type-2 diabetes patients inadequately controlled on metformin.
It was the first clinical trial to combine the two different anti-diabetes medicines. The study was carried out over a 28-week treatment period, with an extension to two years, and enrolled nearly 700 patients in six countries.
Click on this link for more information.
